Cellectis (NASDAQ:CLLS) Upgraded at Zacks Investment Research

Cellectis (NASDAQ:CLLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm currently has a $15.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 12.95% from the company’s previous close.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

Several other brokerages have also recently commented on CLLS. ValuEngine upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Tuesday. BTIG Research initiated coverage on Cellectis in a report on Friday, August 9th. They set a “buy” rating and a $37.00 target price on the stock. Finally, Goldman Sachs Group set a $20.00 price target on Cellectis and gave the company a “hold” rating in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.33.

Shares of CLLS stock traded down $0.29 during trading hours on Tuesday, hitting $13.28. 124,700 shares of the company’s stock were exchanged, compared to its average volume of 119,290. The stock’s 50-day moving average is $10.91 and its 200-day moving average is $14.23. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.99 and a quick ratio of 7.93. The stock has a market cap of $554.82 million, a price-to-earnings ratio of -6.88 and a beta of 1.77. Cellectis has a 52 week low of $9.50 and a 52 week high of $26.17.

A number of institutional investors have recently bought and sold shares of CLLS. Cubist Systematic Strategies LLC bought a new position in Cellectis in the second quarter valued at about $103,000. Aperio Group LLC bought a new position in Cellectis in the second quarter valued at about $147,000. A.R.T. Advisors LLC bought a new position in Cellectis in the second quarter valued at about $171,000. OneAscent Financial Services LLC bought a new position in Cellectis in the second quarter valued at about $257,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Cellectis in the second quarter valued at about $502,000. Institutional investors and hedge funds own 32.13% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Recommended Story: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit